{"id":"W4415941465","doi":"10.1016/j.annonc.2025.08.3036","title":"2421P Sacituzumab Tirumotecan (sac-TMT) + Pembrolizumab (Pembro) in metastatic castration-resistant prostate cancer (mCRPC): Results from phase II MK-2870-002/SKB264-II-06 Study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kelowna General Hospital","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Prostate cancer; Cohort; Cancer; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009178844,0.0008631196,0.001483133,0.0002821134,0.0002507645,0.0008829251,0.0006740129,0.0005653974,0.003681116],"category_scores_gemma":[0.0004980186,0.0002827788,0.001039967,0.0003980706,0.0003712674,0.0005257261,0.0002599073,0.00206199,0.001461781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007335588,"about_ca_system_score_gemma":0.0009640785,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001546872,"about_ca_topic_score_gemma":0.004337276,"domain_scores_codex":[0.9997582,0.00009158551,0.00001083528,0.00004339834,0.00003925345,0.00005682651],"domain_scores_gemma":[0.9997417,0.00002929158,0.00004506369,0.00001871317,0.00001930276,0.0001458698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5173301,0.03482605,0.008425966,0.002332539,0.004564247,0.0003071426,0.0001819449,0.00633407,0.06187056,0.0006595483,0.02504309,0.3381248],"study_design_scores_gemma":[0.5684127,0.3423432,0.04648511,0.0001483162,0.003226737,0.0008966061,0.0001064868,0.003708715,0.009615675,0.0005719386,0.02441266,0.00007186888],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795716,0.009679744,0.0004449288,0.000780912,0.0002603195,0.001009198,0.00300752,0.0002058458,0.005040031],"genre_scores_gemma":[0.9720908,0.009533969,0.001612207,0.001105125,0.0002761612,0.0008124999,0.007172078,0.00007684679,0.007320241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003681116,"threshold_uncertainty_score":0.01231456,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1073835757706979,"score_gpt":0.4626057644084199,"score_spread":0.355222188637722,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}